Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00581763 · ClinicalTrials.gov registry record
Long-Term Outcome of Children and Adolescents With Anti-Phospholipid Antibodies
A clinical trial, sponsored by University of California, San Francisco.
- Completed
- Registry status
- 110
- Enrollment target
NCT00581763: Completed study, sponsored by University of California, San Francisco.
NCT00581763 is a clinical trial that has completed, run by University of California, San Francisco. The registered enrollment target is 110 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00581763 has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- 110 participants
- Enrollment target
Study Summary
This is a study about why some people have certain types of proteins in their blood, called anti-phospholipid antibodies. The presence of these antibodies and associated complications (e.g. blood clots) are known to change over time. The purpose of this study is to evaluate these changes and improve our ability to determine the long-term outcome of affected individuals.
Primary Outcome
blood clot
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2001-05 |
| Est. Completion | 2019-12-20 |
What the finished NCT00581763 record still lists
NCT00581763 is an observational study that tracks outcomes without assigning an intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00581763 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00581763 about?
NCT00581763 is a clinical study titled "Long-Term Outcome of Children and Adolescents With Anti-Phospholipid Antibodies". This is a study about why some people have certain types of proteins in their blood, called anti-phospholipid antibodies. The presence of these antibodies and associated complications (e.g. blood clots) are known to change over time. The purpose of this study is to evaluate these changes and improve...
What is the current status of trial NCT00581763?
This trial is currently completed. The enrollment target is 110 participants. The study started on 2001-05. Estimated completion is 2019-12-20.
Who is sponsoring clinical trial NCT00581763?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia